Relypsa

edit

Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa’s lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

Milestones

edit

• 
  Relypsa received $33M in Series A funding. (10/29/07)
  Posted 3/11/09 at 9:52am

Videos

Screenshots

edit

Traffic Analytics

Compete

Sources

1. Amgen, Relypsa and the art of the biotech-spinout-startup-restart (venturebeat.com) [edit]